OS Therapies Incorporated於2018年4月12日在特拉華州成立。該公司是一家臨床階段的生物製藥公司,專註於骨肉瘤和其他實體瘤治療的鑒定、開發和商業化。他們目前正尋求用他們的主要核心候選產品OST-HER2(也稱為OST31-164)來響應新療法的號召。他們打算用這種候選產品將他們的管道從骨肉瘤擴展到其他具有相同複發作用機制的實體瘤,包括乳腺癌、食管癌和肺癌。
董事
名稱
職位
Colin Goddard
Chairman of the Board
Paul A. Romness
Founder, President, Chief Executive Officer and Director
Joacim Borg
Director
John Ciccio
Director
Theodore F. Search
Director
股東
名稱
職位
Paul A. Romness
Founder, President, Chief Executive Officer and Director
Christopher P. Acevedo
Chief Financial Officer
Gerald Commissiong
Chief Business Officer
Robert G. Petit
Chief Medical Officer and Chief Scientific Officer